I believe we are talking about same study... ended at the 27 patients and not continuing to second half... some good results, but more time is needed. Not new news (so maybe we are talking different)... I have been adding at these low levels, market cap is beyond ridiculous.
- 7 patients or 26% exhibited stable disease. Interestingly, several patients had pretty durable disease stabilization with 22% of patients being on the study beyond 24 weeks.
- median overall survival was 21 months which is much higher than we would expect in this patient population. Because this was a single institution study, we had the opportunity to look at subsequent therapies that the patient received and saw significant responses even to standard chemotherapy, often to drugs that patients had already received.
- Many of the patients went on to receive several lines of therapy and had durable benefit from each of these therapy lines. These findings, while from a relatively small cohort, highlight that cancer immunotherapies can make a durable impact on tumor biology even without an objective response and may affect responses to subsequent treatments.
- We are in the process of performing translational studies to delineate whether the responses to the vaccine or the vaccine-immunotherapy combination were predictive of clinical benefit during the trial and perhaps, predictive of the benefit to subsequent chemotherapies. it would also be prudent to evaluate the vaccine in combination with chemotherapy to see if responses to chemotherapy, or perhaps, the durability of chemotherapy benefit could be improved with this combination.
I couldn’t find the original release, but below is where I am grabbing the quotes from. Nothing new, but interesting to see longer term analysis.
News 
Market Data 
Discover 
